Wells Fargo & Company Begins Coverage on LeMaitre Vascular (NASDAQ:LMAT)

Equities researchers at Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note issued to investors on Thursday, Marketbeat.com reports. The firm set an “equal weight” rating and a $95.00 price target on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective suggests a potential downside of 3.70% from the company’s previous close.

A number of other equities analysts have also commented on the company. Barrington Research raised their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Oppenheimer reissued an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $98.65 on Thursday. LeMaitre Vascular has a one year low of $59.87 and a one year high of $109.58. The business has a fifty day moving average price of $95.99 and a 200-day moving average price of $93.49. The firm has a market capitalization of $2.22 billion, a P/E ratio of 53.91, a PEG ratio of 2.19 and a beta of 0.96.

Institutional Investors Weigh In On LeMaitre Vascular

Hedge funds have recently added to or reduced their stakes in the company. Townsquare Capital LLC lifted its stake in LeMaitre Vascular by 38.0% during the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock worth $4,454,000 after purchasing an additional 13,210 shares during the last quarter. Barclays PLC lifted its stake in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in LeMaitre Vascular by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after purchasing an additional 11,395 shares during the last quarter. Creative Planning lifted its stake in LeMaitre Vascular by 20.7% during the third quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after purchasing an additional 617 shares during the last quarter. Finally, Copeland Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after buying an additional 11,318 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.